Patterns of opioid use in sickle cell disease

American Journal of Hematology

Volumn 91, Issue 11, 2016, Pages 1102-1106

  Han, Jin ^a   Saraf, Santosh L ^a   Zhang, Xu ^a   Gowhari, Michel ^a   Molokie, Robert E ^a,b   Hassan, Joharah ^a   Alhandalous, Chaher ^a   Jain, Shivi ^a   Younge, Jewel ^a   Abbasi, Taimur ^a   Machado, Roberto F ^a   Gordeuk, Victor R ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; BILIRUBIN GLUCURONIDE; COCODAMOL; CODEINE; FENTANYL; HEMOGLOBIN; HYDROCODONE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; HYDROMORPHONE; HYDROXYUREA; LACTATE DEHYDROGENASE; METHADONE; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; TAPENTADOL; TRAMADOL; NARCOTIC ANALGESIC AGENT; VITAMIN D;

ADULT; ARTICLE; AVASCULAR NECROSIS; DRUG MEGADOSE; DRUG USE; FEMALE; HEMOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PRESCRIPTION; PRIORITY JOURNAL; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; SICKLE CELL BETA THALASSEMIA; VEIN OCCLUSION; ANEMIA, SICKLE CELL; ARTERIAL OCCLUSIVE DISEASES; BLOOD; CLINICAL PRACTICE; COHORT ANALYSIS; MIDDLE AGED; NECROSIS; PATHOLOGY; TIME FACTOR; UNITED STATES; YOUNG ADULT;

ADULT; ANALGESICS, OPIOID; ANEMIA, SICKLE CELL; ARTERIAL OCCLUSIVE DISEASES; BILIRUBIN; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NECROSIS; PAIN; PRACTICE PATTERNS, PHYSICIANS'; TIME FACTORS; UNITED STATES; VITAMIN D; YOUNG ADULT;

EID: 84991825009     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24498     Document Type: Article

References (45)

1. Steinberg MH. Management of sickle cell disease. N Engl J Med 1999;340:1021–1030.
2. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008;86:480–487.
3. Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010;38:S512–S521.
4. Lanzkron S, Carroll CP, Haywood C. Jr.: The burden of emergency department use for sickle-cell disease: An analysis of the national emergency department sample database. Am J Hematol 2010;85:797–799.
5. Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009;84:323–327.
6. Ballas SK, Gupta K, Adams-Graves P. Sickle cell pain: A critical reappraisal. Blood 2012;120:3647–3656.
7. Anie KA, Grocott H, White L, Dzingina M, Rogers G, Cho G. Patient self-assessment of hospital pain, mood and health-related quality of life in adults with sickle cell disease. BMJ Open 2012;2.
8. Solomon LR. Pain management in adults with sickle cell disease in a medical center emergency department. J Natl Med Assoc 2010;102:1025–1032.
9. Tanabe P, Martinovich Z, Buckley B, Schmelzer A, Paice JA. Safety of an ED high-dose opioid protocol for sickle cell disease pain. J Emerg Nurs 2015;41:227–235.
10. Ballas SK, Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: Frequency, etiology, and prognostic significance. Am J Hematol 2005;79:17–25.
11. Nielsen S, Degenhardt L, Hoban B, Gisev N. Comparing Opioids: A guide to Estimating Oral Morphine Equivalents (OME) in Research; 2014. Available at: https://ndarc.med.unsw.w?>edu.au/sites/default/files/ndarc/resources/TR.329.pdf
12. Minniti CP, Sable C, Campbell A, Rana S, Ensing G, Dham N, Onyekwere O, Nouraie M, Kato GJ, Gladwin MT, Castro OL, Gordeuk VR. Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: Association with hemolysis and hemoglobin oxygen desaturation. Haematologica 2009;94:340–7.
13. Barcellini W, Fattizzo B. Clinical applications of hemolytic markers in the differential diagnosis and management of hemolytic anemia. Dis Markers 2015;2015:635–670
14. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364:1343–1360.
15. Yoon SL, Black S. Comprehensive, integrative management of pain for patients with sickle-cell disease. J Altern Complement Med 2006;12:995–1001.
16. Dampier C, Ely E, Brodecki D, O'Neal P. Home management of pain in sickle cell disease: A daily diary study in children and adolescents. J Pediatr Hematol Oncol 2002;24:643–647.
17. Smith WR, McClish DK, Dahman BA, Levenson JL, Aisiku IP, de ACV, Bovbjerg VE, Roberts JD, Penberthy LT, Roseff SD. Daily home opioid use in adults with sickle cell disease: The PiSCES project. J Opioid Manag 2015;11:243–253.
18. Dumas EO, Pollack GM. Opioid tolerance development: A pharmacokinetic/pharmacodynamic perspective. Aaps J 2008;10:537–551.
19. Campbell G, Nielsen S, Larance B, Bruno R, Mattick R, Hall W, Lintzeris N, Cohen M, Smith K, Degenhardt L. Pharmaceutical opioid use and dependence among people living with chronic pain: Associations observed within the pain and opioids in treatment (POINT) cohort. Pain Med 2015;16:1745–1758.
20. Chang SC, Ma CC, Lee CT, Hsieh SW. Pharmacoepidemiology of chronic noncancer pain patients requiring chronic opioid therapy: A nationwide population-based study. Acta Anaesthesiol Taiwan 2015;53:89–94.
21. Morasco BJ, Cavanagh R, Gritzner S, Dobscha SK. Care management practices for chronic pain in veterans prescribed high doses of opioid medications. Fam Pract 2013;30:671–678.
22. Busse JW, Mahmood H, Maqbool B, Maqbool A, Zahran A, Alwosaibai A, Alshaqaq E, Persaud N, Cooper L, Carol A, Sumpton J, McGinnis E, Rosenbaum D, Lidster N, Buckley DN. Characteristics of patients receiving long-term opioid therapy for chronic noncancer pain: A cross-sectional survey of patients attending the Pain Management Centre at Hamilton General Hospital, Hamilton, Ontario. CMAJ Open 2015;3:E324–E330.
23. Cunningham JL, Hayes SE, Townsend CO, Laures HJ, Hooten WM. Associations between spousal or significant other solicitous responses and opioid dose in patients with chronic pain. Pain Med (Malden, Mass) 2012;13:1034–1039.
24. Marschall U, L'Hoest H, Radbruch L, Hauser W. Long-term opioid therapy for chronic non-cancer pain in Germany. Eur J Pain 2015;20:767–776.
25. Arthur J, Yennurajalingam S, Nguyen L, Tanco K, Chisholm G, Hui D, Bruera E. The routine use of the Edmonton classification system for cancer pain in an outpatient supportive care center. Palliat Support Care 2014; 1–8.
26. Nguyen LM, Rhondali W, De la Cruz M, Hui D, Palmer L, Kang DH, Parsons HA, Bruera E. Frequency and predictors of patient deviation from prescribed opioids and barriers to opioid pain management in patients with advanced cancer. J Pain Symptom Manage 2013;45:506–516.
27. Vigano A, Bruera E, Suarez-Almazor ME. Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer 1998;83:1244–1250.
28. Alsirafy SA, Galal KM, Abou-Elela EN, Ibrahim NY, Farag DE, Hammad AM. The use of opioids at the end-of-life and the survival of Egyptian palliative care patients with advanced cancer. Ann Palliat Med 2013;2:173–177.
29. Pina P, Sabri E, Lawlor PG. Characteristics and associations of pain intensity in patients referred to a specialist cancer pain clinic. Pain Res Manag 2015;20:249–254.
30. Milner PF, Kraus AP, Sebes JI, Sleeper LA, Dukes KA, Embury SH, Bellevue R, Koshy M, Moohr JW, Smith J. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991;325:1476–1481.
31. Dampier C, Lieff S, LeBeau P, Rhee S, McMurray M, Rogers Z, Smith-Whitley K, Wang W. Health-related quality of life in children with sickle cell disease: A report from the Comprehensive Sickle Cell Centers Clinical Trial Consortium. Pediatr Blood Cancer 2010;55:485–494.
32. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev 2007;21:37–47.
33. Osunkwo I, Ziegler TR, Alvarez J, McCracken C, Cherry K, Osunkwo CE, Ofori-Acquah SF, Ghosh S, Ogunbobode A, Rhodes J, Eckman JR, Dampier C, Tangpricha V. High dose vitamin D therapy for chronic pain in children and adolescents with sickle cell disease: Results of a randomized double blind pilot study. Br J Haematol 2012;159:211–215.
34. Osunkwo I, Hodgman EI, Cherry K, Dampier C, Eckman J, Ziegler TR, Ofori-Acquah S, Tangpricha V. Vitamin D deficiency and chronic pain in sickle cell disease. Br J Haematol 2011;153:538–540.
35. Mukisi-Mukaza M, Saint Martin C, Etienne-Julan M, Donkerwolcke M, Burny ME, Burny F. Risk factors and impact of orthopaedic monitoring on the outcome of avascular necrosis of the femoral head in adults with sickle cell disease: 215 patients case study with control group. Orthop Traumatol Surg Res 2011;97:814–820.
36. Akinyoola AL, Adediran IA, Asaleye CM. Avascular necrosis of the femoral head in sickle cell disease in Nigeria: A retrospective study. Niger Postgrad Med J 2007;14:217–220.
37. Goodman BM, 3rd Artz N, Radford B Chen IA. Prevalence of vitamin D deficiency in adults with sickle cell disease. J Natl Med Assoc 2010;102:332–335.
38. Elmariah H, Garrett ME, De Castro LM, Jonassaint JC, Ataga KI, Eckman JR, Ashley-Koch AE, Telen MJ. Factors associated with survival in a contemporary adult sickle cell disease cohort. Am J Hematol 2014;89:530–535.
39. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf 2014;23:43–50.
40. Nath KA, Hebbel RP. Sickle cell disease: Renal manifestations and mechanisms. Nat Rev Nephrol 2015;11:161–171.
41. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639–1644.
42. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-2009). Pediatr Blood Cancer 2013;60:1482–1486.
43. Wehling M. Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: Management and mitigation of risks and adverse effects. Eur J Clin Pharmacol 2014;70:1159–1172.
44. Kaye AM, Kaye AD, Lofton EC. Basic concepts in opioid prescribing and current concepts of opioid-mediated effects on driving. Ochsner J 2013;13:525–532.
45. U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER): Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use—Labeling for Products That Contain Acetaminophen Guidance for Industry, 2015. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm310477.pdf